Objective: To evaluate the clinical outcome of Botulinum toxin A(BTX-A) with oral baclofen for patients with detrusor overactivity secondary to spinal cord injury(SCI). Methods: A total of 9 SCI patients (mean age, 32 years ;male 7, female 2) with urodynamic detrusor overactivity were included into the study between June 2017 and June 2019. All the patients received BTX-A intradetrusor injections and baclofen. Patients were evaluated at baseline, and 4 weeks after injection. The efficacy and safety outcomes included voiding diary, urodynamic data. Adverse events were also recorded. Results: Compared to the baseline data, the patients’ incontinence quality of life(I-QOL) score, mean maximum detrusor pressure (MDP) and mean maximum cystometric capacity (MCC) improved significantly at 4-week follow-up.No adverse and toxic effect was observed. Conclusions: The treatment of BTX-A with baclofen is effective and safe for patients with detrusor overactivity secondary to SCI. However, it is necessary to observe its long term outcome.
Tianhai Huang, Hui Chen, Xinghua Yang, Maping Huang, Xiaoyi Yang, Qingqing Li, Qiuling Liu, Yanyan Chen, Xiaoxia Su, Xihui Xiao, Weibing Zeng, Cai QT. The treatment of Botulinum toxin A injections and baclofen for patient with detrusor overactivity secondary to spinal cord injury. International Journal of Surgery Research, Volume 2, Issue 1, 2020, Pages 09-11